80 related articles for article (PubMed ID: 10327060)
1. Medullary thyroid carcinomas in transgenic mice expressing a Polyoma carboxyl-terminal truncated middle-T and wild type small-T antigens.
Felici A; Giorgio M; Krauzewicz N; Della Rocca C; Santoro M; Rovere P; Manni I; Amati P; Pozzi L
Oncogene; 1999 Apr; 18(14):2387-95. PubMed ID: 10327060
[TBL] [Abstract][Full Text] [Related]
2. Expression of v-Ha-ras driven by the calcitonin/calcitonin gene-related peptide promoter: a novel transgenic murine model for medullary thyroid carcinoma.
Johnston D; Hatzis D; Sunday ME
Oncogene; 1998 Jan; 16(2):167-77. PubMed ID: 9464534
[TBL] [Abstract][Full Text] [Related]
3. Modulation of medullary thyroid carcinoma penetrance suggests the presence of modifier genes in a RET transgenic mouse model.
Cranston AN; Ponder BA
Cancer Res; 2003 Aug; 63(16):4777-80. PubMed ID: 12941793
[TBL] [Abstract][Full Text] [Related]
4. Hyperplasia in multiple smooth muscle tissues in transgenic mice expressing a temperature-sensitive SV40 T-antigen under the control of smooth muscle alpha-actin regulatory sequences.
March KL; Sandusky G; Fan L
Oncogene; 1999 Jun; 18(25):3773-82. PubMed ID: 10391686
[TBL] [Abstract][Full Text] [Related]
5. Pituitary neoplasia induced by expression of human neurotropic polyomavirus, JCV, early genome in transgenic mice.
Gordon J; Del Valle L; Otte J; Khalili K
Oncogene; 2000 Oct; 19(42):4840-6. PubMed ID: 11039901
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
[TBL] [Abstract][Full Text] [Related]
7. The SV40 small t-antigen prevents mammary gland differentiation and induces breast cancer formation in transgenic mice; truncated large T-antigen molecules harboring the intact p53 and pRb binding region do not have this effect.
Goetz F; Tzeng YJ; Guhl E; Merker J; Graessmann M; Graessmann A
Oncogene; 2001 Apr; 20(18):2325-32. PubMed ID: 11402328
[TBL] [Abstract][Full Text] [Related]
8. Transgenic mice carrying a murine amylase 2.2/SV40 T antigen fusion gene develop pancreatic acinar cell and stomach carcinomas.
Ceci JD; Kovatch RM; Swing DA; Jones JM; Snow CM; Rosenberg MP; Jenkins NA; Copeland NG; Meisler MH
Oncogene; 1991 Feb; 6(2):323-32. PubMed ID: 1705690
[TBL] [Abstract][Full Text] [Related]
9. Tissue specificity of oncogene action: endothelial cell tumours in polyoma middle T transgenic mice.
Bautch VL; Toda S; Hassell JA; Hanahan D
IARC Sci Publ; 1989; (96):255-66. PubMed ID: 2807487
[TBL] [Abstract][Full Text] [Related]
10. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice.
Yamazaki M; Akahane T; Buck T; Yoshiji H; Gomez DE; Schoeffner DJ; Okajima E; Harris SR; Bunce OR; Thorgeirsson SS; Thorgeirsson UP
Carcinogenesis; 2004 Sep; 25(9):1735-46. PubMed ID: 15166086
[TBL] [Abstract][Full Text] [Related]
11. Interference of mouse polyomavirus with the c-myc gene and its product in mouse mammary adenocarcinomas.
Holländerová D; Raslová H; Blangy D; Forstová J; Berebbi M
Int J Oncol; 2003 Aug; 23(2):333-41. PubMed ID: 12851682
[TBL] [Abstract][Full Text] [Related]
12. Developmental analysis of bone tumors in polyomavirus transgenic mice.
Wang R; Siegal GP; Scott DL; Bautch VL
Lab Invest; 1994 Jan; 70(1):86-94. PubMed ID: 8302023
[TBL] [Abstract][Full Text] [Related]
13. Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene.
Coppée F; Gérard AC; Denef JF; Ledent C; Vassart G; Dumont JE; Parmentier M
Oncogene; 1996 Oct; 13(7):1471-82. PubMed ID: 8875985
[TBL] [Abstract][Full Text] [Related]
14. Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter.
Rochefort P; Caillou B; Michiels FM; Ledent C; Talbot M; Schlumberger M; Lavelle F; Monier R; Feunteun J
Oncogene; 1996 Jan; 12(1):111-8. PubMed ID: 8552381
[TBL] [Abstract][Full Text] [Related]
15. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium.
Russell JP; Powell DJ; Cunnane M; Greco A; Portella G; Santoro M; Fusco A; Rothstein JL
Oncogene; 2000 Nov; 19(50):5729-35. PubMed ID: 11126359
[TBL] [Abstract][Full Text] [Related]
16. Tumorigenesis in transgenic mice in which the SV40 T antigen is driven by the brain-specific FGF1 promoter.
Chiu IM; Touhalisky K; Liu Y; Yates A; Frostholm A
Oncogene; 2000 Dec; 19(54):6229-39. PubMed ID: 11175337
[TBL] [Abstract][Full Text] [Related]
17. Adrenocortical tumorigenesis in transgenic mice: the role of luteinizing hormone receptor and transcription factors GATA-4 and GATA-61.
Rahman NA; Kiiveri S; Siltanen S; Levallet J; Kero J; Lensu T; Wilson DB; Heikinheimo MT; Huhtaniemi IT
Reprod Biol; 2001 Jul; 1(1):5-9. PubMed ID: 14666170
[TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
19. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
20. Smooth muscle and bone neoplasms in transgenic mice expressing SV40 T antigen.
Wilkie TM; Schmidt RA; Baetscher M; Messing A
Oncogene; 1994 Oct; 9(10):2889-95. PubMed ID: 8084593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
